Dec 01,2022

AutoZone Partners With Virta Health to Help AutoZoners Reverse Type 2 Diabetes and Prediabetes

Type 2 diabetes reversal leader Virta Health revealed promising one-year outcomes from its partnership with AutoZone, Inc., a retailer and distributor of automotive replacement parts and accessories in the Americas. Last twelve months, AutoZoners living with type 2 diabetes, prediabetes, and obesity have achieved transformative results with Virta, and the Company has shared some results from the partnership.

PRODUCT

#coaching

#virtual care

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

Babyl & Novo Nordisk partner to provide an innovative approach to diabetes awareness and care in Rwanda

Babyl, a subsidiary of Babylon, and Novo Nordisk announced today that they have entered a partnership to contribute to the expansion of diabetes awareness and care in Rwanda. To support the initiative, Babyl will be rolling out a training scheme for clinicians to digitally provide diabetes care for patients, drawing on Novo Nordisk’s global expertise and best practices. By offering digital consultations to patients across Rwanda, Babyl’s service will support people in better understanding the symptoms that they are experiencing as well as supporting patients with a confirmed diabetes diagnosis to manage their chronic condition from the ease and privacy of their own mobile phone.

COLLABORATION PARTNERSHIP

#r&d

#virtual care

View Analyst & Ambassador Comments
Go to original news
Dec 02,2022

Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Better Therapeutics, Inc. today announced that the compensation committee of Better Therapeutics’ board of directors approved the grant of a nonqualified stock option exercisable for 200,000 shares of Better Therapeutics’ common stock to Diane Gomez-Thinnes, Chief Commercial Officer, under the company’s 2022 Inducement Plan, effective on December 1, 2022. The stock option was granted as an inducement material to Ms. Gomez-Thinnes becoming an employee of Better Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

View Analyst & Ambassador Comments
Go to original news
Dec 02,2022

Nemaura Medical to Present at the Planet MIcroCap Showcase

Nemaura Medical, developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 02,2022

Global Smart Insulin Pens & Pumps Market 2022 to 2027 - Featuring Becton, Dickinson and Company, Biocon, DDM Health and Digital Medics Among Others - ResearchAndMarkets.com

The Global Smart Insulin Pens & Pumps Market is estimated to be USD 248.12 Mn in 2022 and is expected to reach USD 478.15 Mn by 2027, growing at a CAGR of 14.02%.

#insulin pen

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Dec 05,2022

Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using AI

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence. In findings presented Friday at the NeurIPS conference in New Orleans, Klick scientists revealed how they used machine learning and just 12 hours of data from CGMs to determine whether a patient was prediabetic or diabetic. Jeon said they discovered their 12-hour model showed similar high accuracy to results from the longer intervals, correctly identifying two-thirds of patients with prediabetes, while also showing high accuracy in identifying healthy patients and those with Type 2 diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial

The objective of the study is to assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes.

CLINICAL STUDY

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes

Current studies on continuous glucose monitor (CGM) uptake are revealing for significant barriers and inequities for CGM use among patients from socially underprivileged communities. This study explores the effect of full subsidies regardless of diabetes type on CGM uptake and HbA1c outcomes in a U.S. adult patient population on Medicaid.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

The diaTribe Foundation, Advanced Technologies & Treatments for Diabetes (ATTD), and the Time in Range Coalition announced today a new international consensus regarding continuous glucose monitoring (CGM) metrics for clinical trials to help accelerate the development of new and improved treatments for people living with diabetes. There is international recognition of the importance of TIR as an actionable metric for daily diabetes management and a means to improve long-term health outcomes. As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 07,2022

Amalgam Rx Named to the 2022 CB Insights’ Digital Health 150 List

CB Insights today named Amalgam Rx to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES